Iteos Therapeutics (ITOS) Corporate Presentation summary

Strategic highlights and financial position

• Anticipates 2025 as a pivotal year with multiple clinical data readouts and over 400 patients enrolled in TIGIT:PD-1 trials for NSCLC and HNSCC.

• Holds approximately $624M in cash, cash equivalents, and short-term investments, with a projected runway through 2027.

• Pipeline includes first-in-class opportunities targeting TIGIT, ENT1, and TREM2, aiming to address resistance and enhance T cell function.

• Collaboration with GSK leverages the TIGIT/CD226 axis for innovative immuno-oncology therapies.

• Focused on impactful milestones in clinical development and data generation across multiple programs.

Clinical development and trial updates

• GALAXIES Lung-201 (Phase 2) is the largest TIGIT trial in PD-L1 high 1L NSCLC, with multiple dosing cohorts and combination arms, currently enrolling.

• GALAXIES Lung-301 (Phase 3) is a double-blind, placebo-controlled trial comparing belrestotug+dostarlimab to pembrolizumab, targeting 1,000 patients.

• GALAXIES H&N-202 (Phase 2) and TIG-006 (Phase 2) are enrolling in 1L HNSCC, evaluating combinations with novel IO agents and different PD-L1 expression levels.

• EOS-984 (ENT1 inhibitor) and EOS-215 (TREM2 antagonist) are in Phase 1 trials for advanced solid tumors, assessing safety, PK/PD, and early efficacy.

• Data readouts from key trials are expected throughout 2025, with interim and topline results anticipated for major programs.

Key clinical results and differentiation

• Belrestotug is the first TIGIT antibody to demonstrate robust target engagement, high affinity, and Treg depletion at all doses.

• Combination of belrestotug+dostarlimab shows strong efficacy in 1L NSCLC, with ORR up to 76.7% and consistent deep tumor reduction across doses.

• Enhanced ctDNA reduction and molecular response rates observed with higher belrestotug doses in combination therapy.

• Safety profile of belrestotug+dostarlimab is broadly consistent with known checkpoint inhibitor combinations, with most irAEs being manageable skin and endocrine disorders.

• EOS-984 restores T cell proliferation in the tumor microenvironment, enhancing anti-PD-1 activity in preclinical models.